$71.14
0.35% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US03940C1009
Symbol
ACLX

Arcellx Stock price

$71.14
+6.45 9.97% 1M
+6.38 9.85% 6M
-5.55 7.24% YTD
+12.49 21.30% 1Y
+49.10 222.78% 3Y
+56.14 374.27% 5Y
+56.14 374.27% 10Y
+56.14 374.27% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.25 0.35%
ISIN
US03940C1009
Symbol
ACLX
Industry

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$3.4b
Net debt
positive
Cash
$543.3m
Shares outstanding
55.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
51.0 | 55.7
EV/Sales
44.0 | 48.0
EV/FCF
negative
P/B
9.4
Financial Health
Equity Ratio
63.9%
Return on Equity
-23.6%
ROCE
-35.6%
ROIC
-448.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$76.8m | $70.6m
EBITDA
$-184.7m | $-216.7m
EBIT
$-190.7m | $-242.0m
Net Income
$-162.4m | $-229.0m
Free Cash Flow
$-122.5m
Growth (TTM | estimate)
Revenue
-41.7% | -34.6%
EBITDA
-153.8% | -63.7%
EBIT
-153.4% | -75.9%
Net Income
-221.4% | -113.4%
Free Cash Flow
-269.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-240.5% | -306.8%
EBIT
-248.2%
Net
-211.5% | -324.3%
Free Cash Flow
-159.5%
More
EPS
$-2.9
FCF per Share
$-2.2
Short interest
15.2%
Employees
130
Rev per Employee
$830.0k
Show more

Is Arcellx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Arcellx Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Arcellx forecast:

Buy
96%
Hold
4%

Financial data from Arcellx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
77 77
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 92 92
25% 25%
120%
- Research and Development Expense 176 176
32% 32%
229%
-185 -185
154% 154%
-240%
- Depreciation and Amortization 5.94 5.94
140% 140%
8%
EBIT (Operating Income) EBIT -191 -191
153% 153%
-248%
Net Profit -162 -162
221% 221%
-211%

In millions USD.

Don't miss a Thing! We will send you all news about Arcellx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcellx Stock News

Neutral
Seeking Alpha
18 days ago
Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data support the potential of anito-cel, especially in 2nd-line+ multiple myeloma patients who failed prior therapies. The FDA has allowed a dual primary endpoint—progression-free survival and MRD-negativit...
Negative
Investors Business Daily
about one month ago
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Neutral
Business Wire
2 months ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Pr...
More Arcellx News

Company Profile

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Rami Elghandour
Employees 130
Founded 2014
Website www.arcellx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today